Imetelstat(GRN163L), a Telomerase Inhibitor Selectively ...Imetelstat (GRN163L), a Telomerase...
1
Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Megakaryopoiesis in Myeloproliferative Neoplasms (MPN) Camelia Iancu-Rubin 1 , Goar Mosoyan 1 , Craig Parker 2 , Kevin Eng 2 and Ronald Hoffman 1 1 Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2 Geron Corporation, Menlo Park, CA, USA ABSTRACT Conflict-of-interest disclosure: C. Iancu-Rubin: research support, R. Hoffman: consultancy, C. Parker and K. Eng: employment; Geron Corporation SUMMARY AND CONCLUSIONS Imetelstat-mediated inhibition of telomerase affects normal megakaryopoiesis by blocking the terminal maturation of CD34 + /CD41 + MK precursors, providing a possible explanation for Imetelstat’s propensity to induce thrombocytopenia in patients with normal marrow. Imetelstat treatment inhibited the ability of MPN CD34 + cells but not normal CD34 + cells to form CFU-MK colonies and drug treatment reduced the numbers of malignant MK generated. We propose that the amelioration of fibrosis observed in a clinical trial of MF patients treated with Imetelstat might be due to, at least in part, two potential modes of action: 1) inhibiting malignant MK progenitors cells 2) preventing terminal MK maturation thus depleting the pool of mature MK which are the major source of fibrogenic cytokines in MF 0 50 100 150 200 250 300 350 400 450 Number of CFU-MK Formed/13x10 3 CD34 + Cells Large CFU-MK Medium CFU-MK Small CFU-MK Untreated MM1 15 µM GRN163L 15µM Figure 1. Imetelstat does not affect the ability of normal PB-CD34 + cells to form CFU-MK. (A) Quantification and morphological appearance (B) of CFU-MK colonies formed by untreated CD34 + cells and by CD34 + cells treated with GRN163L or the inactive form of the drug (MM1). A B EXPERIMENTAL DESIGN GRN163L Primary CD34 + or MNC from healthy controls and MPN patients Immature MK MK Progenitors Mature MK 14-16 days with TPO, Il-3&Il-6 Platelets 1 st Step: 7 days with TPO&SCF 2 nd Step: 7-9 days with TPO only Liquid Culture Semisolid Culture GRN163L GRN163L Imetelstat is a telomerase inhibitor which has been shown to have therapeutic activity in patients with myelofibrosis (MF) (Tefferi A. et al., 2013 ASH Annual Meeting, Abstract 662) and essential thrombocythemia (ET) (Baerlocher G. et al., 2012 ASH Annual Meeting, Abstract 179). In clinical trials involving patients with a variety of other malignancies, the primary dose-limiting toxicity of GRN163L has been thrombocytopenia. We utilized GRN163L in order to explore the possible role of telomerase on human megakaryocytes (MK) and the mechanisms underlying the drug’s inhibitory effects on platelet production. MK were generated from normal primary CD34 + cells using an ex vivo culture system previously described by our laboratory (Iancu-Rubin C. et al, Blood 2011, 117:17; 4580-4589). We first showed that both telomerase activity and the expression of its catalytic unit hTERT were elevated in proliferating normal CD34 + cells, declined transiently during the initial stages of MK differentiation but were then partially restored during the final stages of terminal maturation. Treatment of normal CD34 + cells with GRN163L did not affect the numbers of CFU-MK assayed. Furthermore, exposure to GRN163L during the first 7 days in a liquid culture system did not interfere with the ability of CD34 + cells to commit to MK. When the same cultures were allowed to mature for 7 additional days, the proportion of CD34 + /CD41 + MK precursors in drug-treated cultures was twice that observed in control and the drug-treated cultures contained 70% fewer mature CD41 + /CD42b + MK than control cultures. The inhibitory effects of GRN163L on MK maturation were supported by observations showing that the cultures treated with the drug contained 60% fewer polyploid MK than control cultures. These results suggest that that GRN163L- mediated inhibition of telomerase does not affect normal MK progenitors but blocks the maturation of MK precursor cells. Previous studies have shown that GRN163L inhibits neoplastic CFU-MK colony formation by CD34 + cells from patients with ET (Brunold C. et al., 2011 ASH Annual Meeting, Abstract 3843). We, therefore, examined the effects of GRN163L on malignant MK from patients with MF and ET. Unlike normal CD34 + cells, treatment of MPN PB-MNCs with GRN163L decreased the numbers of assayable CFU-MK from 6 out of 11 patients. CFU-MK colony formation by PB-MNCs from these 6 patients was reduced by 33% (ranging from 13% to 50% reduction in CFU-MK formation) as compared to PB-MNCs treated with an inactive form of the drug (p value= 0.00473). Of note, in two out of 5 patients in which the total number of CFU-MK was not affected by GRN163L treatment, the drug decreased the size of the CFU-MK colonies formed. The ability of MPN PB-MNCs to differentiate into MK was next assessed. Although the total number of cells in PB-MNC liquid cultures exposed to GRN163L was decreased as compared to those treated with the inactive drug (n=6; p value=0.03204), the proportion of CD34 + /CD41 + MK precursors generated was not significantly affected. We then evaluated the effects of GRN163L on the genotype of MPN MK generated in the presence and absence of GRN163L by assessing the JAK2V617F allele burden. Treatment with GRN163L but not the inactive form of the drug reduced the JAK2V617F allele burden in MK derived from two patients: in one patient, JAK2V617F allele burden in MK generated in the presence of the inactive drug was 91.86% while MK generated in the presence of GRN163L was 19.75%; MK generated from a second patient had a JAK2V617F allele burden of 10.84% in the presence of the inactive drug which was reduced to 2.14% in the presence of GRN163L. We conclude that GRN163L-mediated inhibition of telomerase affects normal megakaryopoiesis by blocking the terminal maturation of CD34 + /CD41 + MK precursors, providing a possible explanation for GRN163L’s propensity to induce thrombocytopenia in patients with normal marrow. By contrast, GRN163L treatment inhibited the ability of MPN CD34 + cells but not normal CD34 + cells to form CFU-MK colonies and drug treatment reduced the numbers of malignant MKs generated. We propose that the amelioration of fibrosis observed in a clinical trial of MF patients treated with GRN163L might be due to, at least in part, two potential modes of action: 1) inhibiting malignant MK progenitors cells and 2) preventing terminal MK maturation thus depleting the pool of mature MKs which are the major source of fibrogenic cytokines in MF. A B CD34 CD41 Day 7 Day 14 CD42b CD41 Day 14 Untreated MM1 15 µM GRN163L 15 µM Figure 2. Treatment with Imetelstat during MK differentiation of CD34 + cells results in accumulation of immature CD34 + /CD41 + MK and reduced number of mature CD41 + /CD42 + MK suggesting a delay in MK maturation. (A) Flow cytometric analyses of day 7 and day 14 MK cultures generated in the absence (Untreated) and in the presence of the inactive (MM1) or active drug (GRN163L). (B) Quantification of CD34 + /CD41 + MK precursors (upper panel) and of CD41 + /CD42 + mature MK (lower panel) generated in the absence (untreated) or presence of increasing concentrations of MM1 or GRN163L. 0 1 2 3 4 5 6 % of CD34 + /CD41 + MK Precursors (Fold Change) Absolute cell number (x10 5 ) 0 0.5 1 1.5 2 2.5 3 % of Mature CD41 + /CD42 + Mature MK (Fold Change) 0 5 10 15 20 25 Untreated MM1 7.5 µM MM1 15 µM GRN163L 7.5 µM GRN163L 15 µM % CD61+ MK with >4N DNA Content 25.2% >4N 23.1% >4N 8.9% >4N Untreated MM1 GRN163L Figure 3. Imetelelstat treatment impairs MK polyploidization and morphological maturation. (A) Representative DNA content histograms of immunomagnetically isolated CD61 + MK (day 11) allowed to undergo polyploidization in the absence (Untreated) or presence of GRN163L or its active form (MM1). (B) Quantitative analysis of MK polyploidization indicating the fraction of CD61 + MK with more than 4N DNA content in untreated cultures and cultures treated with MM1 or GRN163L. (C) Morphological appearance of MK cultures generated in the absence (Untreated) and in the presence of GRN163L or its inactive form (MM1). Untreated MM1 15 µM GRN163L 15µM A B C 0.E+00 1.E-05 2.E-05 3.E-05 4.E-05 5.E-05 6.E-05 Relative amount of hTERT mRNA 15 18 21 24 27 30 Real-time Ct SYBR Figure 4. Imetelstat inhibits telomerase expression (hTERT) and activity (TA) and induces DNA damage in HEL JAK2V617F cells. (A) Western blot analyses of protein lysate from HEL JAK2V617F cells untreated (Un) or treated with GRN163L or with its inactive form (MM1). (B) hTERT mRNA expression and telomerase activity (TA) in untreated and treated HEL JAK2V617F cells. TA was evaluated by a PCR-based assay in which the relative enzymatic activity is determined based on the enzyme’s ability to synthetize telomeric repeats which were quantified by PCR; the higher the number of PCR cycles (C t SYBR) required for telomeric sequences amplification, the lower the TA. hTERT mRNA # of PCR cycles hTERT PARP γH2A GAPDH Un MM1 GRN163L A B JAK2V617F Allele Burden (%) Untreated GRN163L-treated Pt6 34.37 19.75 Pt9 7.14 2.14 Pt141 45.17 42.14 Untreated MM1 GRN163L PT5 PT141 CD41-FITC CD42-APC Figure 6. Imetelstat impairs MPN megakaryopoiesis by reducing the number of MK generated and by preventing their terminal maturation. (A) and (B) PB-MNCs from MPN patients (n=8) were plated in liquid culture in the absence (untreated) and in the presence of inactive (MM1) or active drug (GRN163L). After 7 days, viable cells were enumerated (A) and the percentage of CD34 + /CD41 + MK precursors (B) was determined by flow cytometry. (C) Representative examples of dot plot analyses of mature MK (CD41 + /CD42 + ) generated after 14 days in culture by PB-MNC from two MPN patients. Table 2. Imetelstat treatment reduces JAK2V617F allele burden in MK derived from MPN MNC. Mutated JAK2 allele burden was determined on DNA extracted from untreated or GRN163L-treated MK cultures generated by PB-MNC from three JAK2V617F-positive MPN patients. p=0.055 3-13% reduction Ave. = 6.25% p=0.040 13-50% reduction Ave. = 33.08% p=0.0047 Un MM1 GRN163L Macroscopic 10x 0 100 200 300 400 500 600 700 800 Untreated MM1 7.5 mM MM1 15mM GRN163L 7.5 mM GRN163L 15 mM Small Medium Large Number of CFU-MK formed Figure 5. MPN CFU-MK formation is more sensitive to Imetelstat treatment than CFU-MK formation by healthy controls (HC). (A) and (B) CFU-MK formation by PB- MNC from healthy controls (HC, n=4)) and from MPN patients (n=11) grown in the presence of the inactive (MM1) or active drug (GRN163L) as described in Table 1. (C ) Representative example of CFU-MK formed by MNC from PT141 in which the size but not the number of CFU-MK was affected by the drug. A B C Table 1. Imetelstat treatment inhibits CFU-MK formation by MPN MNC. PB-MNC from MPN patients were plated in collagen-based MegaCult media (Stem Cell Technologies) in the absence or presence of drugs. After 14 days, CFU-MK formed were labeled with anti-GPIIIa/IIb antibodies and enumerated. CFU-MK formation efficiency was determined by normalizing the numbers of CFU-MK found in treated cultures to those found in untreated conditions which were considered 100% CFU-MK formation efficiency. Efficiency of CFU-MK formation MM1 GRN163L Outcome Pt2 99.3 54.8 45% reduction Pt3 92 94 No response Pt141 78.5 91 No response for total CFU-MK number Reduced CFU-MK size Pt59 54.8 66 No response for total CFU-MK number Reduced CFU-MK size Pt49 99 49.6 50% reduction Pt138 145 97.9 32.5% reduction Pt5 9.5 20.5 No Response Pt94 129.7 141.4 No response Pt7 96.6 93 13% reduction PT8 97.5 84.1 14% reduction Pt9 119.6 66.6 44% reduction A B C Absolute cell number (x10 5 ) JAK2V617F Allele Burden (%) Untreated GRN163L-treated Pt6 34.37 19.75 Pt9 7.14 2.14 Pt141 45.17 42.14
Transcript of Imetelstat(GRN163L), a Telomerase Inhibitor Selectively ...Imetelstat (GRN163L), a Telomerase...
Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Megakaryopoiesis in Myeloproliferative Neoplasms (MPN)Camelia Iancu-Rubin1, Goar Mosoyan1, Craig Parker2, Kevin Eng2 and Ronald Hoffman1
1Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;2Geron Corporation, Menlo Park, CA, USA
ABSTRACT
Conflict-of-interest disclosure: C. Iancu-Rubin: research support, R. Hoffman: consultancy, C. Parker and K. Eng: employment; Geron Corporation
SUMMARY AND CONCLUSIONS
Imetelstat-mediated inhibition of telomerase affects normal megakaryopoiesis by blocking theterminal maturation of CD34+/CD41+ MK precursors, providing a possible explanation forImetelstat’s propensity to induce thrombocytopenia in patients with normal marrow.
Imetelstat treatment inhibited the ability of MPN CD34+ cells but not normal CD34+ cells toform CFU-MK colonies and drug treatment reduced the numbers of malignant MK generated.
We propose that the amelioration of fibrosis observed in a clinical trial of MF patients treatedwith Imetelstat might be due to, at least in part, two potential modes of action:1) inhibiting malignant MK progenitors cells 2) preventing terminal MK maturation thus depleting the pool of mature MK which are the major source of fibrogenic cytokines in MF
0
50
100
150
200
250
300
350
400
450
Num
ber o
f CFU
-MK
Form
ed/1
3x10
3 CD
34+
Cells
Large CFU-MK
Medium CFU-MK
Small CFU-MK
Untreated MM1 15 µM GRN163L 15µM
Figure 1. Imetelstat does not affect the ability of normal PB-CD34+ cells toform CFU-MK. (A) Quantification and morphological appearance (B) of CFU-MKcolonies formed by untreated CD34+ cells and by CD34+ cells treated withGRN163L or the inactive form of the drug (MM1).
A B
EXPERIMENTAL DESIGNGRN163L
PrimaryCD34+ or MNCfrom healthy
controls and MPN patients
Immature MK
MK Progenitors
Mature MK
14-16 days with TPO, Il-3&Il-6
Platelets
1st Step: 7 days with TPO&SCF 2nd Step: 7-9 days with TPO onlyLiquid Culture
Semisolid Culture
GRN163L
GRN163L
Imetelstat is a telomerase inhibitor which has been shown to have therapeutic activity in patients withmyelofibrosis (MF) (Tefferi A. et al., 2013 ASH Annual Meeting, Abstract 662) and essential thrombocythemia(ET) (Baerlocher G. et al., 2012 ASH Annual Meeting, Abstract 179). In clinical trials involving patients with avariety of other malignancies, the primary dose-limiting toxicity of GRN163L has been thrombocytopenia. Weutilized GRN163L in order to explore the possible role of telomerase on human megakaryocytes (MK) and themechanisms underlying the drug’s inhibitory effects on platelet production. MK were generated from normalprimary CD34+ cells using an ex vivo culture system previously described by our laboratory (Iancu-Rubin C. etal, Blood 2011, 117:17; 4580-4589). We first showed that both telomerase activity and the expression of itscatalytic unit hTERT were elevated in proliferating normal CD34+ cells, declined transiently during the initialstages of MK differentiation but were then partially restored during the final stages of terminal maturation.Treatment of normal CD34+ cells with GRN163L did not affect the numbers of CFU-MK assayed. Furthermore,exposure to GRN163L during the first 7 days in a liquid culture system did not interfere with the ability ofCD34+ cells to commit to MK. When the same cultures were allowed to mature for 7 additional days, theproportion of CD34+/CD41+ MK precursors in drug-treated cultures was twice that observed in control and thedrug-treated cultures contained 70% fewer mature CD41+/CD42b+ MK than control cultures. The inhibitoryeffects of GRN163L on MK maturation were supported by observations showing that the cultures treated withthe drug contained 60% fewer polyploid MK than control cultures. These results suggest that that GRN163L-mediated inhibition of telomerase does not affect normal MK progenitors but blocks the maturation of MKprecursor cells.
Previous studies have shown that GRN163L inhibits neoplastic CFU-MK colony formation by CD34+ cells frompatients with ET (Brunold C. et al., 2011 ASH Annual Meeting, Abstract 3843). We, therefore, examined theeffects of GRN163L on malignant MK from patients with MF and ET. Unlike normal CD34+ cells, treatment ofMPN PB-MNCs with GRN163L decreased the numbers of assayable CFU-MK from 6 out of 11 patients. CFU-MKcolony formation by PB-MNCs from these 6 patients was reduced by 33% (ranging from 13% to 50% reductionin CFU-MK formation) as compared to PB-MNCs treated with an inactive form of the drug (p value= 0.00473).Of note, in two out of 5 patients in which the total number of CFU-MK was not affected by GRN163Ltreatment, the drug decreased the size of the CFU-MK colonies formed. The ability of MPN PB-MNCs todifferentiate into MK was next assessed. Although the total number of cells in PB-MNC liquid cultures exposedto GRN163L was decreased as compared to those treated with the inactive drug (n=6; p value=0.03204), theproportion of CD34+/CD41+ MK precursors generated was not significantly affected. We then evaluated theeffects of GRN163L on the genotype of MPN MK generated in the presence and absence of GRN163L byassessing the JAK2V617F allele burden. Treatment with GRN163L but not the inactive form of the drug reducedthe JAK2V617F allele burden in MK derived from two patients: in one patient, JAK2V617F allele burden in MKgenerated in the presence of the inactive drug was 91.86% while MK generated in the presence of GRN163Lwas 19.75%; MK generated from a second patient had a JAK2V617F allele burden of 10.84% in the presence ofthe inactive drug which was reduced to 2.14% in the presence of GRN163L.We conclude that GRN163L-mediated inhibition of telomerase affects normal megakaryopoiesis by blockingthe terminal maturation of CD34+/CD41+ MK precursors, providing a possible explanation for GRN163L’spropensity to induce thrombocytopenia in patients with normal marrow. By contrast, GRN163L treatmentinhibited the ability of MPN CD34+ cells but not normal CD34+ cells to form CFU-MK colonies and drugtreatment reduced the numbers of malignant MKs generated. We propose that the amelioration of fibrosisobserved in a clinical trial of MF patients treated with GRN163L might be due to, at least in part, two potentialmodes of action: 1) inhibiting malignant MK progenitors cells and 2) preventing terminal MK maturation thusdepleting the pool of mature MKs which are the major source of fibrogenic cytokines in MF.
A B
CD34CD
41
Day 7 Day 14
CD42b
CD41
Day 14
Untreated
MM1 15 µM
GRN163L 15 µM
Figure 2. Treatment with Imetelstat during MK differentiation of CD34+
cells results in accumulation of immature CD34+/CD41+ MK andreduced number of mature CD41+/CD42+ MK suggesting a delay in MKmaturation. (A) Flow cytometric analyses of day 7 and day 14 MKcultures generated in the absence (Untreated) and in the presence of theinactive (MM1) or active drug (GRN163L). (B) Quantification ofCD34+/CD41+ MK precursors (upper panel) and of CD41+/CD42+ matureMK (lower panel) generated in the absence (untreated) or presence ofincreasing concentrations of MM1 or GRN163L.
0
1
2
3
4
5
6
% o
f CD
34+ /
CD41
+ M
K Pr
ecur
sors
(F
old
Chan
ge)
Absolute cell number (x105)
0
0.5
1
1.5
2
2.5
3
% o
f Mat
ure
CD41
+ /CD
42+
Mat
ure
MK
(Fol
d Ch
ange
)
0
5
10
15
20
25
Untreated MM1 7.5µM
MM1 15µM
GRN163L7.5 µM
GRN163L15 µM
% C
D61
+ M
K w
ith >
4N D
NA
Cont
ent
25.2%>4N 23.1%
>4N8.9%>4N
Untreated MM1 GRN163L
Figure 3. Imetelelstat treatment impairs MKpolyploidization and morphological maturation.(A) Representative DNA content histograms ofimmunomagnetically isolated CD61+ MK (day 11) allowedto undergo polyploidization in the absence (Untreated) orpresence of GRN163L or its active form (MM1). (B)Quantitative analysis of MK polyploidization indicating thefraction of CD61+ MK with more than 4N DNA content inuntreated cultures and cultures treated with MM1 orGRN163L. (C) Morphological appearance of MK culturesgenerated in the absence (Untreated) and in the presenceof GRN163L or its inactive form (MM1).
Untreated MM1 15 µM GRN163L 15µMA
B C
0.E+00
1.E-05
2.E-05
3.E-05
4.E-05
5.E-05
6.E-05
Rela
tive
amou
nt o
f hTE
RTm
RNA
15
18
21
24
27
30
Real
-tim
e Ct
SYB
R
Figure 4. Imetelstat inhibits telomerase expression (hTERT) and activity (TA) and induces DNA damage in HEL JAK2V617F cells.(A) Western blot analyses of protein lysate from HEL JAK2V617F cells untreated (Un) or treated with GRN163L or with its inactive form (MM1).(B) hTERT mRNA expression and telomerase activity (TA) in untreated and treated HEL JAK2V617F cells. TA was evaluated by a PCR-based assay inwhich the relative enzymatic activity is determined based on the enzyme’s ability to synthetize telomeric repeats which were quantified by PCR;the higher the number of PCR cycles (Ct SYBR) required for telomeric sequences amplification, the lower the TA.
hTERT mRNA # of PCR cycleshTERT
PARP
γH2A
GAPDH
Un MM1 GRN163LA B
JAK2V617F Allele Burden (%)
Untreated GRN163L-treated
Pt6 34.37 19.75
Pt9 7.14 2.14
Pt141 45.17 42.14
Untreated MM1 GRN163L
PT5
PT141
CD41-FITC
CD42
-APC
Figure 6. Imetelstat impairs MPN megakaryopoiesis by reducing the number of MK generated and by preventing their terminalmaturation. (A) and (B) PB-MNCs from MPN patients (n=8) were plated in liquid culture in the absence (untreated) and in the presenceof inactive (MM1) or active drug (GRN163L). After 7 days, viable cells were enumerated (A) and the percentage of CD34+/CD41+ MKprecursors (B) was determined by flow cytometry. (C) Representative examples of dot plot analyses of mature MK (CD41+/CD42+)generated after 14 days in culture by PB-MNC from two MPN patients.
Table 2. Imetelstat treatment reduces JAK2V617F allele burden in MKderived from MPN MNC. Mutated JAK2 allele burden was determinedon DNA extracted from untreated or GRN163L-treated MK culturesgenerated by PB-MNC from three JAK2V617F-positive MPN patients.
p=0.055
3-13% reductionAve. = 6.25%
p=0.040
13-50% reductionAve. = 33.08%
p=0.0047
Un MM1 GRN163L
Macroscopic
10x
0
100
200
300
400
500
600
700
800
Untreated MM1 7.5mM
MM115mM
GRN163L7.5 mM
GRN163L15 mM
Small
Medium
Large
Num
bero
f CFU
-MK
form
ed
Figure 5. MPN CFU-MK formation is more sensitive to Imetelstat treatment thanCFU-MK formation by healthy controls (HC). (A) and (B) CFU-MK formation by PB-MNC from healthy controls (HC, n=4)) and from MPN patients (n=11) grown in thepresence of the inactive (MM1) or active drug (GRN163L) as described in Table 1.(C ) Representative example of CFU-MK formed by MNC from PT141 in which the sizebut not the number of CFU-MK was affected by the drug.
A B C
Table 1. Imetelstat treatment inhibits CFU-MK formation byMPN MNC. PB-MNC from MPN patients were plated incollagen-based MegaCult media (Stem Cell Technologies) inthe absence or presence of drugs. After 14 days, CFU-MKformed were labeled with anti-GPIIIa/IIb antibodies andenumerated. CFU-MK formation efficiency was determined bynormalizing the numbers of CFU-MK found in treated culturesto those found in untreated conditions which were considered100% CFU-MK formation efficiency.
Efficiency of CFU-MKformation
MM1 GRN163L Outcome
Pt2 99.3 54.8 45% reduction
Pt3 92 94 No response
Pt141 78.5 91No response for total CFU-MK numberReduced CFU-MK size
Pt59 54.8 66No response for total CFU-MK numberReduced CFU-MK size
Pt49 99 49.6 50% reduction
Pt138 145 97.9 32.5% reduction
Pt5 9.5 20.5 No Response
Pt94 129.7 141.4 No response
Pt7 96.6 93 13% reduction
PT8 97.5 84.1 14% reduction
Pt9 119.6 66.6 44% reduction
A B C
Absolute cell number (x105)
JAK2V617F Allele Burden (%)
Untreated GRN163L-treated
Pt6 34.37 19.75
Pt9 7.14 2.14
Pt141 45.17 42.14
